DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
about
Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesAspects of T Cell-Mediated Immunity Induced in Mice by a DNA Vaccine Based on the Dengue-NS1 Antigen after Challenge by the Intracerebral RouteA genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in immunocompetent miceInduction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines.Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccineThe synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Circulation of different lineages of Dengue virus 2, genotype American/Asian in Brazil: dynamics and molecular and phylogenetic characterization.Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challengeDistinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2Cooperation between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a DNA Vaccine Based on the NS1 AntigenThe Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in MiceGeneration and characterization of a monoclonal antibody against duck Tembusu virus envelope protein.Dengue severity associated with age and a new lineage of dengue virus-type 2 during an outbreak in Rio De Janeiro, Brazil.Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein
P2860
Q27304342-19E9230C-4655-4672-A73A-BD39CD11797EQ27321668-2D58BC3B-7C7B-4B0B-B092-305AF0432C9FQ28483765-D151CF68-96C8-492B-8BE9-32879CECD8B8Q34059579-E76502B1-71ED-4366-9BF1-E2603B28738BQ34262245-23E58DB2-D55B-486C-8F1B-6DD5D7D5020CQ34614953-BBFADE45-6A3F-415C-9685-1D22A6DA66CCQ34637823-68CA7394-9D60-447B-95E1-7A76974C3034Q34855420-82A5A58A-30D5-4F12-B005-5A353327DD38Q35624552-91A945FB-BB7C-4DFE-82AB-6FDBF37D8AFFQ35864468-18803C46-B7B3-48B9-A0DF-08AC702C2D92Q35880666-DDB5996C-B8C3-4A8B-88FE-DECE1B9D820AQ38721146-83A3461A-9EB6-429B-937D-EB4F967A542AQ40110519-F3E1F4CE-B4C4-4D11-8A19-3DF45B0CB5E2Q41921198-7D5406C2-9B3B-4660-A201-F62323DB63F2
P2860
DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
DNA vaccines against dengue vi ...... ope protein or its domain III.
@ast
DNA vaccines against dengue vi ...... ope protein or its domain III.
@en
type
label
DNA vaccines against dengue vi ...... ope protein or its domain III.
@ast
DNA vaccines against dengue vi ...... ope protein or its domain III.
@en
prefLabel
DNA vaccines against dengue vi ...... ope protein or its domain III.
@ast
DNA vaccines against dengue vi ...... ope protein or its domain III.
@en
P2093
P2860
P1433
P1476
DNA vaccines against dengue vi ...... ope protein or its domain III.
@en
P2093
Ada M B Alves
Adriana S Azevedo
Anna M Y Yamamura
Gisela F Trindade
Marcos S Freire
P2860
P304
P356
10.1371/JOURNAL.PONE.0020528
P407
P577
2011-07-11T00:00:00Z